HRP20191793T1 - Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja - Google Patents

Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja Download PDF

Info

Publication number
HRP20191793T1
HRP20191793T1 HRP20191793TT HRP20191793T HRP20191793T1 HR P20191793 T1 HRP20191793 T1 HR P20191793T1 HR P20191793T T HRP20191793T T HR P20191793TT HR P20191793 T HRP20191793 T HR P20191793T HR P20191793 T1 HRP20191793 T1 HR P20191793T1
Authority
HR
Croatia
Prior art keywords
insulin
derivative
specified intervals
intended
average
Prior art date
Application number
HRP20191793TT
Other languages
English (en)
Croatian (hr)
Inventor
Thue Johansen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11776766.5A external-priority patent/EP2632478B1/en
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HRP20191793T1 publication Critical patent/HRP20191793T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HRP20191793TT 2010-10-27 2019-10-03 Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja HRP20191793T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40720610P 2010-10-27 2010-10-27
EP11170366 2010-10-27
EP10189115 2010-10-27
US201161498645P 2011-06-20 2011-06-20
EP11776766.5A EP2632478B1 (en) 2010-10-27 2011-10-27 Treating diabetes melitus using insulin injections administered with varying injection intervals
PCT/EP2011/068870 WO2012055967A2 (en) 2010-10-27 2011-10-27 Treating diabetes melitus using insulin injections administered with varying injection intervals

Publications (1)

Publication Number Publication Date
HRP20191793T1 true HRP20191793T1 (hr) 2019-12-27

Family

ID=50036508

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191793TT HRP20191793T1 (hr) 2010-10-27 2019-10-03 Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja

Country Status (6)

Country Link
US (1) US10596229B2 (ja)
JP (1) JP6049625B2 (ja)
BR (1) BR112013010345A2 (ja)
DK (1) DK2632478T3 (ja)
HR (1) HRP20191793T1 (ja)
RU (1) RU2013123515A (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3907676A (en) 1970-07-28 1975-09-23 Novo Terapeutisk Labor As Process for purifying insulin
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4876322A (en) 1984-08-10 1989-10-24 Siemens Aktiengesselschaft Irradiation cross-linkable thermostable polymer system, for microelectronic applications
EP0174493B1 (de) 1984-08-17 1988-05-25 Bayer Ag Thermoplastische Formmassen mit flammwidrigen Eigenschaften
DE3433367A1 (de) 1984-09-12 1986-03-20 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur steuerung der energiezufuhr zu einer heissen stelle
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
AU641721B2 (en) 1989-12-21 1993-09-30 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
DK45590D0 (ja) 1990-02-21 1990-02-21 Novo Nordisk As
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
NZ246556A (en) 1991-12-20 1996-03-26 Novo Nordisk As Pharmaceutical composition of a growth hormone and histidine
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
RO112873B1 (ro) 1993-09-17 1998-01-30 Novo Nordisk As Derivati de insulina
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
HUP9800523A3 (en) 1995-03-17 1998-09-28 Novo Nordisk As Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
PT938502E (pt) 1996-07-11 2005-02-28 Novo Nordisk As Metodo selectivo por acilacao
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AU6611898A (en) 1997-03-20 1998-10-20 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
DE69806362T2 (de) 1997-03-20 2003-01-30 Novo Nordisk A/S, Bagsvaerd Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
SI0884053T1 (en) 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
CA2308705A1 (en) 1997-10-24 1999-05-06 Novo Nordisk A/S Aggregates of human insulin derivatives
BR9813111A (pt) 1997-10-24 2000-08-15 Lilly Co Eli Composições de insulina insolúveis
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
BR9914585A (pt) 1998-10-16 2001-07-03 Novo Nordisk As Formulação aquosa de insulina, preparação de insulina, e, método de tratamento de diabetes do tipo i ou do tipo ii
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
ES2180511T3 (es) 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
EP1154796B1 (en) 1999-02-22 2007-06-20 University of Connecticut Novel albumin-free factor viii formulations
WO2000064940A1 (en) 1999-04-27 2000-11-02 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ATE382057T1 (de) 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
US20050014679A1 (en) 2001-12-20 2005-01-20 Beals John Michael Insulin molecule having protracted time action
AU2003208316A1 (en) 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
WO2003094956A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
EP1506003A1 (en) 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
AU2003285075B2 (en) 2002-10-29 2009-10-29 Durect Corporation Stabilized, solid-state polypeptide particles
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
CA2515294A1 (en) 2003-02-07 2004-08-19 Ajinomoto Co., Inc. Therapeutic agents for diabetes
ATE473279T1 (de) 2003-02-19 2010-07-15 Novartis Pharma Gmbh In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
CA2518136A1 (en) 2003-03-04 2004-09-16 The Technology Development Company Ltd. Oral insulin composition and methods of making and using thereof
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
KR101159559B1 (ko) * 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
ES2402592T3 (es) 2003-08-05 2013-05-07 Novo Nordisk A/S Nuevos derivados de insulina
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
WO2005047508A1 (en) 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
WO2005063298A1 (en) 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation
ATE433746T1 (de) 2004-03-12 2009-07-15 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
CN1993138B (zh) 2004-06-01 2010-12-15 阿雷斯贸易股份有限公司 稳定蛋白质的方法
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
CN101039660B (zh) 2004-08-12 2010-10-06 先灵公司 稳定的聚乙二醇化干扰素制剂
EP2311871A3 (en) 2004-08-17 2012-08-08 Regeneron Pharmaceuticals, Inc. IL-1 antagonist stable liquid formulation
ES2575984T3 (es) 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
CA2593112A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
ES2490243T3 (es) 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
CA2626357A1 (en) 2005-10-20 2007-04-26 Nastech Pharmaceutical Company Inc. Intranasal administration of rapid acting insulin
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2007096431A1 (en) 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
CN101454019A (zh) 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
WO2007135117A2 (en) 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
JP5715418B2 (ja) 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
PT2597103T (pt) 2007-11-16 2017-02-08 Novo Nordisk As Composições farmacêuticas contendo insulina e um péptido insulinotrófico
PL2254906T3 (pl) 2008-03-18 2017-04-28 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
RU2540922C2 (ru) 2008-10-30 2015-02-10 Ново Нордиск А/С Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
US20130143803A1 (en) 2010-05-10 2013-06-06 Novo Nordisk A/S Process for the Preparation of Insulin-Zinc Complexes
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
RS59423B1 (sr) 2010-10-27 2019-11-29 Novo Nordisk As Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
CN103459417B (zh) 2011-02-01 2018-04-10 诺沃—诺迪斯克有限公司 胰岛素的纯化
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
US10293109B2 (en) 2011-09-13 2019-05-21 Novo Nordisk A/S Adaptive system for optimizing a drug dosage regimen over time
MX2014012096A (es) 2012-04-11 2014-11-21 Novo Nordisk As Formulaciones de insulina.
AU2013255880B2 (en) 2012-05-01 2017-07-20 Novo Nordisk A/S Pharmaceutical composition
WO2014147141A1 (en) 2013-03-20 2014-09-25 Novo Nordisk A/S Insulin dosing regimen
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime

Also Published As

Publication number Publication date
US10596229B2 (en) 2020-03-24
RU2013123515A (ru) 2014-12-10
JP2014500244A (ja) 2014-01-09
JP6049625B2 (ja) 2016-12-21
US20180125946A1 (en) 2018-05-10
DK2632478T3 (da) 2019-10-07
BR112013010345A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
HRP20191793T1 (hr) Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
WO2012055967A3 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
WO2009129250A3 (en) Meal-time insulin analogues of enhanced stability
JP2011241213A5 (ja)
HRP20151230T1 (hr) Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2
JP2015143253A5 (ja)
BRPI0406499A (pt) Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
ES2334258T3 (es) Control de la glucosa en sangre en el tratamiento de la diabetes que usa la insulina administrada pulmonarmente en combinacion con la insulina basal.
RU2011119988A (ru) Композиции инсулинов длительного действия
HRP20120688T1 (hr) Re“im doziranja u liječenju traumatske ozljede mozga progesteronom
WO2015105981A3 (en) Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment
HUP0100391A2 (hu) Monomer inzulinanalógokat tartalmazó gyógyászati készítmény és alkalmazása
HRP20180468T1 (hr) Novi derivat analoga inzulina
HRP20121029T4 (hr) Liksisenatid kao pomoćna terapija uz inzulin glargin i metformin kod liječenja dijabetesa tip 2
JP2016516076A5 (ja)
PH12015501931B1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
HK1143066A1 (en) Ranolazine for elevated brain-type natriuretic peptide
WO2014145593A3 (en) Site 2 insulin analogues
MX2014013091A (es) Composicion farmaceutica.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
MX2020006658A (es) Tratamiento de hipoglucemia inducida por el ejercicio en la diabetes tipo 1 y tipo 2 en la que se usa insulina.
Nusair Recurrent long-lasting hypoglycemia in a young patient with insulin dependent diabetes mellitus due to lipohypertrophy-an unusual presentation
Povlsen Prolonged increased glucose level: case report